Furthermore, lung cancer specimens and cell lines that developed resistance to ALK inhibitors exhibited increased PD-L1 expression, linking the PD-1/PD-L1 pathway to ALK inhibitor resistance in cases of ALK rearrangement (41). This evidence concerns the gene ALK and lung carcinoma.